Globalization of Biosimilars

This track discuses about the generic drugs impact on global biosimilar market , Cost and risk management, Adopting innovative mechanisms such as risk-sharing arrangement, European market for biosimilars.

The global market scenario with the launch of first biosimilar in the market forecasts some radical changes. This track will look upon such key concerns which are witnessed by the global pharma market and that are coming up with the subsequent launch of the other biosimilars and biologics.Despite these emerging facilities, biotherapeutic developers are most comfortable off-shoring to established markets—the US and Europe.

In terms of the outsourcing destinations that are most-cited as at least a possibility for outsourcing during the next five years, the leading markets are:

USA (78% are at least considering)

Germany (76%)

Singapore (74%)

United Kingdom (73%).

  • Global impact of biosimilars over generics
  • Economic aspect towards biosimilars
  • Biosimilars in global market
  • Investment and returns on biosimilars
  • Cost and risk management
  • Adopting innovative mechanisms such as risk-sharing arrangement
  • Global P&R models for the biosimilars and generics market
  • Uniform Code for Biologics and Biosimilars Marketing Practices

Related Conference of Globalization of Biosimilars

October 16-18, 2017

12th World Pharma Congress

Budapest, Hungary
October 16-18, 2017

11th World Drug Delivery Summit

(10 Plenary Forums - 1Event)
Baltimore, Maryland, USA
October 16-17, 2017

10th International Conference and Exhibition on Biologics and Biosimilars

San Francisco, California, USA
November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Globalization of Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in